Opendata, web and dolomites

AltCheM SIGNED

In vivo functional screens to decipher mechanisms of stochastically- and mutationally-induced chemoresistance in Acute Myeloid Leukemia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AltCheM project word cloud

Explore the words cloud of the AltCheM project. It provides you a very rough idea of what is the project "AltCheM" about.

regardless    cell    intrinsically    aml    screening    fundamental    despite    persistence    combining    consequence    effectors    initial    adults    mutant    exome    few    functional    innovative    decades    stochastically    chemoresistant    vivo    characterization    actively    biological    resistance    experiments    mutational    genesis    leukemia    hematology    cells    libraries    relapse    prone    patients    initiating    agents    acute    predetermined    poorly    screen    resist    chemotherapeutic    emergence    myeloid    chip    chemoresistance    chemoprotective    profiling    mechanisms    reading    fraction    consecutive    pooled    decipher    status    mice    almost    autonomous    therapies    relevance    mouse    rounds    pursue    ultimately    resistant    remission    tested    model    collection    frame    mrd    expansion    residual    molecular    virtue    minimal    underlying    chemotherapy    shrna    re    combinations    standard    therapy    paradigm    modes    treatment    examined    af9    conduct    firmly    survive    mll    genetically    stochastic    diagnosed    disease    sustained    genomic    mutationally    line    sequencing    mutations    front    predict    rna   

Project "AltCheM" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 1˙500˙000 €
 EC max contribution 1˙500˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-STG
 Funding Scheme ERC-STG
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2023-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 1˙500˙000.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Acute Myeloid Leukemia (AML), the most common leukemia diagnosed in adults, represents the paradigm of resistance to front-line therapies in hematology. Indeed, AML is so genetically complex that only few targeted therapies are currently tested in this disease and chemotherapy remains the only standard treatment for AML since the past four decades. Despite an initial sustained remission achieved by chemotherapeutic agents, almost all patients relapse with a chemoresistant minimal residual disease (MRD). The goal of my proposal is to characterize the still poorly understood biological mechanisms underlying persistence and emergence of MRD. MRD is the consequence of the re-expansion of leukemia-initiating cells that are intrinsically more resistant to chemotherapy. This cell fraction may be stochastically more prone to survive front-line therapy regardless of their mutational status (the stochastic model), or genetically predetermined to resist by virtue of a collection of chemoprotective mutations (the mutational model). I have already generated in mice, by consecutive rounds of chemotherapy, a stochastic MLL-AF9-driven chemoresistance model that I examined by RNA-sequencing. I will pursue the comprehensive cell autonomous and cell non-autonomous characterization of this chemoresistant AML disease using whole-exome and ChIP-sequencing. To establish a mutationally-induced chemoresistant mouse model, I will conduct an innovative in vivo screen using pooled mutant open reading frame and shRNA libraries in order to predict which combinations of mutations, among those already known in AML, actively promote chemoresistance. Finally, by combining genomic profiling and in vivo shRNA screening experiments, I will decipher the molecular mechanisms and identify the functional effectors of these two modes of resistance. Ultimately, I will then be able to firmly establish the fundamental relevance of the stochastic and/or the mutational model of chemoresistance for MRD genesis.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ALTCHEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ALTCHEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

KineTic (2020)

New Reagents for Quantifying the Routing and Kinetics of T-cell Activation

Read More  

E-DURA (2018)

Commercialization of novel soft neural interfaces

Read More  

HyperBio (2019)

Vis-NIR Hyperspectral imaging for biomaterial quality control

Read More